Literature DB >> 1627691

Retransplantation following isolated lung transplantation.

J D Miller1, G A Patterson.   

Abstract

The results of retransplantation for early allograft failure are discouraging. Fortunately, with recent technical advances and improved postoperative immunosuppression, airway complications have been significantly reduced. It is now unusual to see patients with airway complications following lung transplantation. This group of patients is not likely to represent a large population in need of retransplantation in the future. However, rejection-mediated OB remains a persistent problem seen in all transplant centers. The group of patients who deteriorate despite augmented immunosuppression will put increasing pressure on transplant programs to provide the only known solution for survival: retransplantation. In the Toronto experience, only 1 patient survived early retransplantation. Three of the 5 recipients retransplanted late in their course have survived and 2 are presently alive and well. Yet this is in sharp contrast to the current 80% 1-year survival for initial transplant recipients. As the demand for donor lungs increases with the growing need for first-time procedures, the use of donor lungs for retransplantation becomes a significant problem. The decision whether to allocate a donor lung (and commit significant hospital resources) to a retransplant recipient or to a first-time recipient is difficult. A patient with early graft failure has a dismal prognosis and a decision not to retransplant may be straightforward. However, the decision to retransplant a patient who has developed OB late following their initial transplant is much more difficult. It is still our responsibility to manage this limited resource and provide donor lungs to those who have the optimal chance of survival.

Entities:  

Mesh:

Year:  1992        PMID: 1627691

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  2 in total

Review 1.  Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies.

Authors:  Andrew I R Scott; Linda D Sharples; Susan Stewart
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Lung retransplantation: walking a thin line between hope and false expectations.

Authors:  Laurent Godinas; Dirk Van Raemdonck; Laurens J Ceulemans; Robin Vos; Geert M Verleden
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.